CN113896882A - 一种聚乙二醇-乙烯基醚衍生物的合成方法 - Google Patents
一种聚乙二醇-乙烯基醚衍生物的合成方法 Download PDFInfo
- Publication number
- CN113896882A CN113896882A CN202111300071.XA CN202111300071A CN113896882A CN 113896882 A CN113896882 A CN 113896882A CN 202111300071 A CN202111300071 A CN 202111300071A CN 113896882 A CN113896882 A CN 113896882A
- Authority
- CN
- China
- Prior art keywords
- polyethylene glycol
- vinyl ether
- ether derivative
- peg
- substituent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 polyethylene Polymers 0.000 title claims abstract description 30
- 239000004698 Polyethylene Substances 0.000 title claims abstract description 29
- 229920000573 polyethylene Polymers 0.000 title claims abstract description 29
- 238000001308 synthesis method Methods 0.000 title abstract description 9
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 80
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 75
- 238000006243 chemical reaction Methods 0.000 claims abstract description 33
- 238000000034 method Methods 0.000 claims abstract description 15
- 125000003827 glycol group Chemical group 0.000 claims abstract description 12
- 239000002904 solvent Substances 0.000 claims abstract description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 8
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 7
- 239000002994 raw material Substances 0.000 claims abstract description 5
- 239000003513 alkali Substances 0.000 claims abstract description 3
- 125000005843 halogen group Chemical group 0.000 claims abstract 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 15
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 14
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 10
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical group [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 8
- 239000012312 sodium hydride Substances 0.000 claims description 8
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 8
- 230000002194 synthesizing effect Effects 0.000 claims description 6
- 229940057838 polyethylene glycol 4000 Drugs 0.000 claims description 5
- 239000002585 base Substances 0.000 claims description 2
- IJJSYKQZFFGIEE-UHFFFAOYSA-N naphthalene;potassium Chemical compound [K].C1=CC=CC2=CC=CC=C21 IJJSYKQZFFGIEE-UHFFFAOYSA-N 0.000 claims description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims description 2
- 238000010189 synthetic method Methods 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 abstract description 10
- 238000003786 synthesis reaction Methods 0.000 abstract description 10
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 36
- 230000002829 reductive effect Effects 0.000 description 17
- 229940079593 drug Drugs 0.000 description 14
- 239000012074 organic phase Substances 0.000 description 12
- 239000003960 organic solvent Substances 0.000 description 12
- 229940126586 small molecule drug Drugs 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- HEDRZPFGACZZDS-MICDWDOJSA-N deuterated chloroform Substances [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- 239000012265 solid product Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 150000002367 halogens Chemical group 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- PPUZXOKAOIOPIE-UHFFFAOYSA-N 1-bromo-2-ethenoxyethane Chemical compound BrCCOC=C PPUZXOKAOIOPIE-UHFFFAOYSA-N 0.000 description 1
- REEBWSYYNPPSKV-UHFFFAOYSA-N 3-[(4-formylphenoxy)methyl]thiophene-2-carbonitrile Chemical compound C1=CC(C=O)=CC=C1OCC1=C(C#N)SC=C1 REEBWSYYNPPSKV-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
- C08G65/3311—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing a hydroxy group
- C08G65/3312—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing a hydroxy group acyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/334—Polymers modified by chemical after-treatment with organic compounds containing sulfur
- C08G65/3344—Polymers modified by chemical after-treatment with organic compounds containing sulfur containing oxygen in addition to sulfur
- C08G65/3346—Polymers modified by chemical after-treatment with organic compounds containing sulfur containing oxygen in addition to sulfur having sulfur bound to carbon and oxygen
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/337—Polymers modified by chemical after-treatment with organic compounds containing other elements
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明公开了一种聚乙二醇‑乙烯基醚衍生物的合成方法,包括以下步骤:以聚乙二醇/聚乙二醇取代物(I)和化合物(II)为反应原料,在碱和溶剂的存在下反应,得到式(III)所示化合物,即为所述聚乙二醇‑乙烯基醚衍生物。本发明聚乙二醇‑乙烯基醚衍生物的合成方法可得到高纯度的聚乙二醇‑乙烯基醚衍生物,其纯度可达98%以上。本发明合成方法均是适合于商业化生产的经济型方法。本发明所涉及的方法,原料简单易得,反应条件温和(室温,常压),最重要的是大大减少了该类聚乙二醇衍生物的合成步骤(一步法);
Description
技术领域
本发明涉及一种聚乙二醇-乙烯基醚衍生物的合成方法,属于聚乙二醇-乙烯基醚衍生物合成技术领域。
背景技术
聚乙二醇(PEG)作为FDA唯一认证可应用于生物医药领域的人工合成高分子材料,具有良好的理化特性和生物相容性,广泛应用于药物制剂、药物缓释及靶向载体,还可以通过共价键偶联于蛋白、多肽及小分子药物。大量研究表明,经过PEG修饰的小分子药物,其抗原性明显降低或消除,水溶性和稳定性增加,药物半衰期大为延长,疗效更好。
为了将聚乙二醇和小分子药物相连接,不仅需要将PEG末端原始羟基改变为不同功能性基团,有时也需要对小分子药物进行二次修饰。为了应对人体内小分子药物的有效释放,需要PEG和小分子药物之间的连接键具有特定生理条件下的响应性断裂。
已报道的特定生理条件响应有pH响应,还原性响应,活性氧响应和温度响应等。部分情况下,小分子药物和PEG断裂后,无法还原成原始小分子药物的化学结构,这可能是因为小分子药物的二次不可逆修饰导致的。这种响应性断裂成非原始结构的小分子药物,必然会影响其疗效和体内药代动力学,造成无法预知的药物风险。虽然部分情况下小分子药物和PEG断裂后,可还原成原始的药物结构,但其PEG和小分子药物的偶联步骤繁琐,纯化困难,生产成本增加和药物杂质的非必要引入,对PEG化小分子药物的实际应用带来困扰。
发明内容
发明目的:为了克服上述问题,本发明提供了一种聚乙二醇-乙烯基醚衍生物的合成方法,其能够解决响应性断裂后小分子药物原始结构还原难的问题,以及简化此种情况下的PEG化药物的合成步骤,所得聚乙二醇-乙烯基醚衍生物可与小分子药物一步偶联且可响应性断裂。
技术方案:一种聚乙二醇-乙烯基醚衍生物的合成方法,包括以下步骤:
以聚乙二醇取代物(I)和化合物(II)为反应原料,在碱和溶剂的存在下反应,得到式(III)所示化合物,即为所述聚乙二醇-乙烯基醚衍生物:
其中,X选自卤素或-OTs,Y选自卤素、-OH或-OTs。
所述X位于PEG的末端位置,X的数量和PEG链的数量有关,由于PEG结构是确定的,所以它的反应位点(-X)也是确定的。当Y选自-OH时,反应物必须为聚乙二醇取代物;当反应物为聚乙二醇时,Y必须选自卤素或-OTs。
优选的,所述聚乙二醇或聚乙二醇取代物(I)中的PEG,其分子量500-100000。
优选的,所述聚乙二醇选自单甲氧基聚乙二醇5000、聚乙二醇2000、四臂聚乙二醇10000、单甲氧基聚乙二醇2000、聚乙二醇4000或聚乙二醇20000;所述聚乙二醇取代物选自单甲氧基聚乙二醇5000、聚乙二醇2000、四臂聚乙二醇10000、单甲氧基聚乙二醇2000、聚乙二醇4000或聚乙二醇20000的取代物。
优选的,所述聚乙二醇/聚乙二醇取代物(I)中,PEG为直链、双链或多链中的一种或多种,呈现星形、树形或分叉形结构中的一种或多种。
优选的,所述碱选自氢化钠、叔丁醇钾和萘钾。
优选的,所述溶剂选自四氢呋喃(THF)和N,N-二甲基甲酰胺(DMF)中的一种或几种的组合。
优选的,所述聚乙二醇/聚乙二醇取代物(I)和化合物(II)的摩尔比为1:3-1:5。
优选的,所述反应的温度为20-30℃(室温),反应的时间为20-30h。
一种聚乙二醇-乙烯基醚衍生物,其结构如下式(III)所示:
其中,PEG为分子量500-100000。
本发明还提供了所述的聚乙二醇-乙烯基醚衍生物在制备pH敏感性药物中的应用。
本发明方法中聚乙二醇可以是直链、双链、多链或者星形、树形、分叉形结构,因此,得到的聚乙二醇-乙烯基醚也可以是直链、双链、多链或者星形、树形、分叉形结构。所合成出的聚乙二醇-乙烯基醚衍生物可以与含羟基药物发生缩醛化反应,形成pH敏感性大分子药物,可在特定pH条件下断裂,游离出自由的药物分子。
有益效果:本发明聚乙二醇-乙烯基醚衍生物的合成方法可得到高纯度的聚乙二醇-乙烯基醚衍生物,其纯度可达98%以上。本发明合成方法均是适合于商业化生产的经济型方法。本发明所涉及的方法,原料简单易得,反应条件温和(室温,常压),最重要的是大大减少了该类聚乙二醇衍生物的合成步骤(一步法)。
具体实施方式
以下通过具体的实施例进一步说明本发明的技术方案。
实施例1:合成单甲氧基聚乙二醇5000-乙烯基醚衍生物
将2-乙烯氧基乙醇(2.64g,30mmol)溶于DMF溶剂中,冰浴下加入氢化钠(1.08g,45mmol),之后继续搅拌30min;将单甲氧基聚乙二醇5000-氯(50g,10mmol)的DMF溶液滴加至上述反应液中,室温继续反应24小时。
反应完毕,淬灭反应液,之后减压回收有机溶剂。残余液加入水和二氯甲烷,分出有机相,无水硫酸钠干燥有机相。减压回收二氯甲烷有机溶剂,之后于冰乙醚中沉淀,沉淀收集后真空干燥得固体产物45g,产率90%。
1H-NMR(CDCl3,400MHz)δ3.65(PEG主链,455H)、δ3.38(CH3 -O-PEG,3H)、δ4.05-4.21(-CH=CH2 ,2H)、δ6.42(-CH=CH2,1H)和δ3.89(-CH2 -O-CH=CH2,2H)
实施例2:合成聚乙二醇2000-乙烯基醚衍生物
将2-乙烯氧基乙醇(2.64g,30mmol)溶于DMF溶剂中,冰浴下加入氢化钠(1.08g,45mmol),之后继续搅拌30min;将聚乙二醇2000-溴(10g,5mmol)的DMF溶液滴加至上述反应液中,室温继续反应24小时。
反应完毕,淬灭反应液,之后减压回收有机溶剂。残余液加入水和二氯甲烷,分出有机相,无水硫酸钠干燥有机相。减压回收二氯甲烷有机溶剂,之后于冰乙醚中沉淀,沉淀收集后真空干燥得固体产物9.2g,产率92%。
H-NMR(CDCl3,400MHz)δ3.65(PEG主链,182H)、δ4.05-4.21(-CH=CH2 ,4H)、δ6.43(-CH=CH2,2H)和δ3.91(-CH2 -O-CH=CH2,4H)
实施例3:合成四臂聚乙二醇10000-乙烯基醚衍生物
将2-乙烯氧基乙醇(2.64g,30mmol)溶于THF溶剂中,冰浴下加入氢化钠(1.08g,45mmol),之后继续搅拌30min;将四臂聚乙二醇10000-对甲苯磺酸酯(25g,2.5mmol)的THF溶液滴加至上述反应液中,室温继续反应24小时。
反应完毕,淬灭反应液,之后减压回收有机溶剂。残余液加入水和二氯甲烷,分出有机相,无水硫酸钠干燥有机相。减压回收二氯甲烷有机溶剂,之后于冰乙醚中沉淀,沉淀收集后真空干燥得固体产物21g,产率84%。
H-NMR(CDCl3,400MHz)δ3.65(PEG主链,909H)、δ3.26(C-CH2-O-,8H),δ4.05-4.21(-CH=CH2 ,8H)、δ6.43(-CH=CH2,4H)和δ3.90(-CH2 -O-CH=CH2,8H)
实施例4:合成单甲氧基聚乙二醇2000-乙烯基醚衍生物
将单甲氧基聚乙二醇2000(20g,10mmol)溶于DMF溶剂中,冰浴下加入氢化钠(0.72g,30mmol),之后继续搅拌2小时;将2-氯乙基乙烯基醚(3.2g,30mmol)的DMF溶液滴加至上述反应液中,室温继续反应24小时。
反应完毕,淬灭反应液,之后减压回收有机溶剂。残余液加入水和二氯甲烷,分出有机相,无水硫酸钠干燥有机相。减压回收二氯甲烷有机溶剂,之后于冰乙醚中沉淀,沉淀收集后真空干燥得固体产物17g,产率85%。
1H-NMR(CDCl3,400MHz)δ3.65(PEG主链,182H)、δ3.38(CH3 -O-PEG,3H)、δ4.05-4.21(-CH=CH2 ,2H)、δ6.42(-CH=CH2,1H)和δ3.89(-CH2 -O-CH=CH2,2H)
实施例5:合成聚乙二醇4000-乙烯基醚衍生物
将聚乙二醇4000(20g,5mmol)溶于THF溶剂中,冰浴下加入氢化钠(0.72g,30mmol),之后继续搅拌2小时;将2-溴乙基乙烯基醚(4.53g,30mmol)的THF溶液缓慢滴加至上述反应液中,室温继续反应24小时。
反应完毕,淬灭反应液,之后减压回收有机溶剂。残余液加入水和二氯甲烷,分出有机相,无水硫酸钠干燥有机相。减压回收二氯甲烷有机溶剂,之后于冰乙醚中沉淀,沉淀收集后真空干燥得固体产物17.5g,产率87.5%。
H-NMR(CDCl3,400MHz)δ3.65(PEG主链,364H)、δ4.05-4.21(-CH=CH2 ,4H)、δ6.43(-CH=CH2,2H)和δ3.91(-CH2 -O-CH=CH2,4H)
实施例6:合成聚乙二醇20000-乙烯基醚衍生物
将聚乙二醇20000(40g,2mmol)溶于THF溶剂中,冰浴下加入氢化钠(0.288g,12mmol),之后继续搅拌2小时;将2-对甲苯磺酸乙基乙烯基醚(2.91g,12mmol)的THF溶液滴加至上述反应液中,室温继续反应24小时。
反应完毕,淬灭反应液,之后减压回收有机溶剂。残余液加入水和二氯甲烷,分出有机相,无水硫酸钠干燥有机相。减压回收二氯甲烷有机溶剂,之后于冰乙醚中沉淀,沉淀收集后真空干燥得固体产物36g,产率90%。
H-NMR(CDCl3,400MHz)δ3.65(PEG主链,1818H)、δ4.05-4.21(-CH=CH2 ,4H)、δ6.42(-CH=CH2,2H)和δ3.89(-CH2 -O-CH=CH2,4H)。
Claims (10)
2.根据权利要求1所述的聚乙二醇-乙烯基醚衍生物的合成方法,其特征在于,所述聚乙二醇或聚乙二醇取代物(I)中的PEG,其分子量为500-100000。
3.根据权利要求1所述的聚乙二醇-乙烯基醚衍生物的合成方法,其特征在于,所述聚乙二醇选自单甲氧基聚乙二醇5000、聚乙二醇2000、四臂聚乙二醇10000、单甲氧基聚乙二醇2000、聚乙二醇4000或聚乙二醇20000;所述聚乙二醇取代物选自单甲氧基聚乙二醇5000、聚乙二醇2000、四臂聚乙二醇10000、单甲氧基聚乙二醇2000、聚乙二醇4000或聚乙二醇20000的取代物。
4.根据权利要求1所述的聚乙二醇-乙烯基醚衍生物的合成方法,其特征在于,所述聚乙二醇/聚乙二醇取代物(I)中,PEG为直链、双链或多链中的一种或多种,呈现星形、树形或分叉形结构中的一种或多种。
5.根据权利要求1所述的聚乙二醇-乙烯基醚衍生物的合成方法,其特征在于,所述碱选自氢化钠、叔丁醇钾或萘钾。
6.根据权利要求1所述的聚乙二醇-乙烯基醚衍生物的合成方法,其特征在于,所述溶剂选自四氢呋喃(THF)和N,N-二甲基甲酰胺(DMF)中的一种或几种的组合。
7.根据权利要求1所述的聚乙二醇-乙烯基醚衍生物的合成方法,其特征在于,所述聚乙二醇/聚乙二醇取代物(I)和化合物(II)的摩尔比为1:3-1:5。
8.根据权利要求1所述的聚乙二醇-乙烯基醚衍生物的合成方法,其特征在于,所述反应的温度为20-30℃,反应的时间为20-30h。
10.权利要求9所述的聚乙二醇-乙烯基醚衍生物在制备pH敏感性药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111300071.XA CN113896882A (zh) | 2021-11-04 | 2021-11-04 | 一种聚乙二醇-乙烯基醚衍生物的合成方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111300071.XA CN113896882A (zh) | 2021-11-04 | 2021-11-04 | 一种聚乙二醇-乙烯基醚衍生物的合成方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113896882A true CN113896882A (zh) | 2022-01-07 |
Family
ID=79028179
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111300071.XA Pending CN113896882A (zh) | 2021-11-04 | 2021-11-04 | 一种聚乙二醇-乙烯基醚衍生物的合成方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113896882A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114656649A (zh) * | 2022-04-24 | 2022-06-24 | 广州格致利康技术有限公司 | 一种基于聚乙二醇的嵌段聚合物-乙烯基醚衍生物及其合成方法和应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101564537A (zh) * | 2009-06-08 | 2009-10-28 | 河北科技大学 | 3,5-二羟基-4-异丙基二苯乙烯-溴乙酸乙酯-聚乙二醇复合物及其合成方法 |
JP2009269846A (ja) * | 2008-05-02 | 2009-11-19 | Osaka Prefecture Univ | 温度感受性リポソーム |
CN102161754A (zh) * | 2010-02-13 | 2011-08-24 | 华中科技大学同济医学院附属协和医院 | 枝化状聚乙二醇衍生物的功能化修饰方法 |
CN107189056A (zh) * | 2017-06-15 | 2017-09-22 | 温州大学 | 一种无双羟基单甲氧基聚乙二醇及其制备方法 |
-
2021
- 2021-11-04 CN CN202111300071.XA patent/CN113896882A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009269846A (ja) * | 2008-05-02 | 2009-11-19 | Osaka Prefecture Univ | 温度感受性リポソーム |
CN101564537A (zh) * | 2009-06-08 | 2009-10-28 | 河北科技大学 | 3,5-二羟基-4-异丙基二苯乙烯-溴乙酸乙酯-聚乙二醇复合物及其合成方法 |
CN102161754A (zh) * | 2010-02-13 | 2011-08-24 | 华中科技大学同济医学院附属协和医院 | 枝化状聚乙二醇衍生物的功能化修饰方法 |
CN107189056A (zh) * | 2017-06-15 | 2017-09-22 | 温州大学 | 一种无双羟基单甲氧基聚乙二醇及其制备方法 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114656649A (zh) * | 2022-04-24 | 2022-06-24 | 广州格致利康技术有限公司 | 一种基于聚乙二醇的嵌段聚合物-乙烯基醚衍生物及其合成方法和应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200138968A1 (en) | Process for preparing intermediate of antibody drug conjugate | |
KR20080036236A (ko) | 말단에 아민기를 갖는 중합체의 제조방법 | |
US8557999B2 (en) | Pharmaceutical, dietary supplement, and food grade salts of anatabine | |
CN103044676B (zh) | 一种聚乙二醇修饰的生物相关物质 | |
CN102367291B (zh) | 含单官能团的多级支化聚乙二醇及其合成方法 | |
CN113896882A (zh) | 一种聚乙二醇-乙烯基醚衍生物的合成方法 | |
CN103044675B (zh) | 一种单一官能化的支化聚乙二醇 | |
CN110078644A (zh) | 一种[2-[1-(Fmoc-氨基)乙氧基]乙氧基]乙酸的制备方法 | |
EP0418925B1 (en) | Method of producing (S)-4-hydroxymethyl-gamma-lactone | |
US20110071262A1 (en) | Method for preparing high-purity polyethyleneglycol aldehyde derivatives | |
CN112441932B (zh) | 一种富马酸比索洛尔杂质的制备方法 | |
CN113264983A (zh) | 一种用于抗体偶联药物的连接子lnd1088的合成方法 | |
CN111936549B (zh) | 包含三苯甲基的单分散聚乙二醇的纯化方法 | |
CN111454180A (zh) | 一种索马鲁肽侧链中间体及其制备方法 | |
US20050203287A1 (en) | Process for the preparation of sulfamate derivatives | |
CN111574463B (zh) | 一种利格列汀中间体化合物ⅳ | |
CN113549054B (zh) | 一种富马酸沃诺拉赞中间体及其制备方法 | |
CN100480252C (zh) | 蔗糖衍生物及其制法和利用蔗糖衍生物合成三氯蔗糖的方法 | |
CN111574520B (zh) | 一种利格列汀中间体化合物ⅴ | |
KR960015107B1 (ko) | 시알로실 글리세리드 및 그의 제조 방법 | |
CN105732338B (zh) | 一种m-PEG聚合物的制备方法 | |
CN101270130A (zh) | 二脂肪酰磷脂酰乙醇胺的制备方法 | |
CN112341354B (zh) | 一种pms的合成方法 | |
CN113563502B (zh) | 固载苯醌氧化剂及其制备方法、合成烟酰胺核糖有机酸盐的用途 | |
CN114306632B (zh) | 一种与人血清白蛋白非共价结合型7-乙基-10-羟基喜树碱衍生物前药、制备及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |